ArticleFrontiers in medicine2025
A case report of leptospirosis complicated by severe pulmonary hemorrhage treated with venovenous extracorporeal membrane oxygenation.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leptospirosis is a zoonotic disease with diverse clinical manifestations, and its severe form can lead to life-threatening complications such as pulmonary hemorrhage. We present a novel case of a 57-year-old woman with leptospirosis who developed severe pulmonary hemorrhage and acute respiratory distress syndrome (ARDS) and was successfully managed with early venovenous extracorporeal membrane oxygenation (VV-ECMO), minimal anticoagulation, and lymphoplasmacyte exchange (LPE). This case highlights the importance of early ECMO initiation, individualized anticoagulation, and immunomodulatory therapy in improving outcomes for patients with leptospiral pulmonary hemorrhage syndrome (LPHS), a condition with mortality exceeding 50%. To our knowledge, this is the first reported case combining VV-ECMO with LPE in LPHS, offering a new therapeutic paradigm for critically ill patients at the intersection of infection and autoimmunity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.